#Stock Dividend #United Kingdom #Edinburgh #TC BioPharm #gamma-delta T cells

TC BioPharm Declares a 25% Stock Dividend

TC BioPharm (Holdings) PLC, a rising name in the clinical biotechnology sector based in Edinburgh, Scotland, recently unveiled an exciting development for its shareholders. The company, known for pioneering gamma-delta T cell therapies aimed at treating various cancers, announced that a special stock dividend of 25% has received formal approval during a General Meeting held on December 30, 2024.

Key Details of the Stock Dividend

The approved special dividend entails providing shareholders with 0.25 American Depositary Shares (ADSs) for every 1 ADS they hold as of January 2, 2025. Shares are expected to be distributed around January 6, 2025. This strategic move highlights the company’s commitment to enhancing shareholder value, reflecting management's strong belief in the long-term financial success of TC BioPharm.

Bryan Kobel, CEO of TC BioPharm, expressed his enthusiasm regarding this decision, stating, "Rewarding additional shares to shareholders in the form of this special dividend is an important and effective component of our capital management strategy. It also reflects management's strong confidence in the Company's financial future. I anticipate 2025 to be a period of growth and development for our Company as we remain focused on delivering improved value for our shareholders."

Impact on Trading

Per Nasdaq's guidelines, trading of the company's ADSs will halt temporarily at 5:00 PM on January 2, 2025, allowing necessary preparations for the dividend distribution. Trading is expected to resume on or around January 8, 2025, with an adjusted opening price to account for the dilution caused by the stock dividend. This proactive adjustment aligns with Nasdaq's policies in ensuring transparency and fairness during such corporate actions.

About TC BioPharm

TC BioPharm specializes in developing allogeneic gamma-delta T cell therapies. These therapies leverage a unique aspect of the immune system that can effectively differentiate between healthy and diseased cells, particularly in the fight against cancer. The company has pioneered clinical trials that position it as a leader in this innovative field, providing hope for patients battling acute myeloid leukemia, among other conditions. Their proprietary technology, CryoTC, aims to deliver these therapies more efficiently and effectively across healthcare settings worldwide.

Looking Ahead

2025 is shaping up to be a pivotal year for TC BioPharm as it continues its path of innovation and development. The recent stock dividend is not just a financial maneuver; it symbolizes a growth-focused strategy that the company firmly endorses. As TC BioPharm pushes further into its clinical trials and expands its outreach with gamma-delta T cell therapies, shareholders can expect both short-term benefits from the dividend and long-term gains as the company's market presence strengthens. With a solid operational strategy backing its mission, TC BioPharm is optimistic about the future and the impact it can make in the biopharmaceutical landscape.

For more information about TC BioPharm’s initiatives and upcoming milestones, interested parties can visit their website. The company continues to release regular updates, maintaining transparency about its journey and achievements.

Final Thoughts

The announcement of a 25% stock dividend marks a significant moment in the landscape of biotechnology investment. For those watching the development of TC BioPharm, this move is a clear indicator of the company's confidence in its future trajectory and financial growth, allowing shareholders to share in the journey ahead. While further details will unfold in the coming months, the sentiment in the market suggests that TC BioPharm is on the right path toward achieving its ambitious goals.